The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer - PubMed (original) (raw)

Review

The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer

Mark J McKeage. Expert Opin Investig Drugs. 2008 Jan.

Abstract

5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is a vascular disrupting agent that has demonstrated efficacy in combination with taxane-based chemotherapy in patients with advanced cancer. Complementary modes of action, a lack of pharmacokinetic interaction and distinct adverse effect profiles provide a strong rationale for combining these anticancer agents. In a Phase II trial in men with hormone refractory prostate cancer, DMXAA (ASA404) in combination with docetaxel achieved a prostate-specific antigen response in more patients than docetaxel therapy alone, and was generally well tolerated. Further clinical evaluation of this combination in this patient population is warranted.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources